Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of SCoK COVID-19 Vaccine in Healthy Adults
NCT04636333Phase 1Unknown
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Oct 2020
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant SARS-CoV-2 vaccine (CHO cell) in coronavirus disease 2019 (COVID-19), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoint: Proportion of adverse reactions at 28 days. Status: unknown.
02
Drugs
recombinant SARS-CoV-2 vaccine (CHO cell)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04636333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04636333.